DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180161

Adjunctive sublingual misoprostol for secondary prevention of post-partum hemorrhage during cesarean delivery: double blind placebo randomized controlled trial

Hany F. Sallam, Nahla W. Shady

Abstract


Background: Cesarean delivery is the most frequently performed major operative procedure worldwide. Objective of present study was to evaluate randomized evidence regarding efficacy and safety of sublingual misoprostol for secondary prevention of post-partum hemorrhage during and after cesarean delivery in women receiving prophylactic oxytocin as primary preventive tools and bleed around 500ml by visual analogue estimation.

Methods: A prospective, randomized, double-blind, placebo-controlled trial was performed at an obstetrics and gynecology department Aswan university hospital, Egypt, between October 2015 and September 2017. Women were eligible if they were undergoing elective cesarean under spinal anesthesia and were bleed around 500ml by visual analogue estimation. All participants received 10 IU oxytocin after delivery of the newborn. Participants were randomly assigned (1:1) to receive 400 μg misoprostol or matched placebo sublingually using a computer-generated random number sequence. Participants and providers were masked to assignment. The primary outcomes were intraoperative and postoperative blood loss.

Results: There was high significant reduction in intraoperative blood loss in misoprostol group (711.0±188.41) compared with placebo group (915.33±293.72) (P=0.0001). The all estimated blood loss during CS and 24 hours postoperative was significant lower in misoprostol group (890.39±194.49) than that in placebo group (1096.9±300.05) (p=0.0001).

Conclusions: Misoprostol as an adjunct to oxytocin as secondary prevention of pot partum hemorrhage seemed to be more effectively reduce blood loss than did placebo with oxytocin alone.


Keywords


Cesarean delivery, Post-partum hemorrhage, Sublingual misoprostol

Full Text:

PDF

References


Tessier V, Pierre F, National College of Gynecologists and Obstetricians French, and National Agency of Accreditation and Evaluation in Health. Risk factors of postpartum hemorrhage during labor and clinical and pharmacological prevention. J Gynecol Obstet Biol Reprod (Paris) 2004 Dec;33(8 Suppl):4S29-56.

Joseph KS, Rouleau J, Kramer MS, Young DC, Liston RM, Baskett TF et al. Investigation of an increase in postpartum haemorrhage in Canada. BJOG. 2007;114:751-9.

Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):999-1012.

Thomas J, Callwood A, Paranjothy S. National Sentinel Caesarean Section Audit: update. Pract Midwife. 2000;3(11):20.

Munn MB, Owen J, Vincent R, Wakefield M, Chestnut DH, Hauth JC. Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a randomized controlled trial. Obstet Gynecol. 2001;98:386-90.

Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean section. Br J Anaesthiol. 2007;98:116-9.

Vimala N, Mittal S, Kumar S. Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynecol Obstet. 2006;92:106-10.

Eftekhari N, Doroodian M, Lashkarizadeh R. The effect of sublingual misoprostol versus intravenous oxytocin in reducing bleeding after caesarean section. J Obstet Gynaecol. 2009;29:633-6.

Chaudhuri P, Banerjee GB, Mandal A. Rectally administered misoprostol versus intravenous oxytocin infusion during cesarean delivery to reduce intraoperative and postoperative blood loss. Int J Gynecol Obstet. 2010;109:25-9.

Owonikoko KM, Arowojolu AO, Okunlola MA. Effect of sublingual misoprostol versus intravenous oxytocin on reducing blood loss at cesarean section in Nigeria: a randomized controlled trial. Obstet Gynaecol Res. 2011;37:715-21.

Hamm J, Russell Z, Botha T, Carlan SJ, Richichi K. Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. Am J Obstet Gynecol. 2005;192:1404-6.

Fekih M, Jnifene A, Fathallah K, Ben Regaya L, Memmi A, Bouguizene S, et al. Benefit of misoprostol for prevention of postpartum hemorrhage in cesarean section: a randomized controlled trial. J Gynecol Obstet Biol Reprod (Paris). 2009;38:588-93.

Quiroga Díaz R, Cantú Mata R, Tello Gutiérrez HE, Puente Villalobos M, Montemayor Garza R, Martínez Mendoza A. Intrauterine misoprostol for the prevention of bleeding cesarean. Ginecol Obstet Mex. 2009;77:469-74.

Chalermpolprapa MD. Efficacy of sublingual misoprostol in prevention of postpartum hemorrhage in cesarean section: a randomized double-blinded, placebo-controlled trial. Med J. 2010;29:325-35.

Sood AK, Singh S. Sublingual misoprostol to reduce blood loss at cesarean delivery. J Obstet Gynaecol India. 2012;62:162-7.

Elsedeek MS. Impact of preoperative rectal misoprostol on blood loss during and after elective cesarean delivery. Int J Gynecol Obstet. 2012;118:149-52.

El Tahan MR, Warda OM, Rashad A, Yasseen AM, Ramzy EA, Ahmady MS, et al. Effects of preoperative sublingual misoprostol on uterine tone during isoflurane anesthesia for cesarean section. Rev Bras Anestesiol. 2012;62:625-35.

Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2007;(3):CD005457.

Lewis G. Saving mother’s lives: reviewing maternal deaths to make motherhood safer—2003–2005. The seventh report of the Confidential Enquiries into maternal deaths in the United Kingdom. London: CEMACH;2007.

Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2014;(2):CD003249.

WHO Guidelines Approved by the Guidelines Review Committee. Who Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: World Health Organization;2012.

Widmer M, Blum J, Hofmeyr GJ, Carroli G, Abdel-Aleem H, Lumbiganon P, et al. Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial. Lancet. 2010;375:1808-13.

Blum J, Winikoff B, Raghavan S, Dabash R, Ramadan MC, Dilbaz B, et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a double-blind placebo-controlled randomized non-inferiority trial among women receiving prophylactic oxytocin. Lancet. 2010;375:217-23.

Winikoff B, Dabash R, Durocher J, Darwish E, Ngoc NTN, León W et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin: results from a double-blind, placebo-controlled, randomized, non-inferiority trial among women not exposed to oxytocin during labor. Lancet. 2010;375:210-6.

Tang OS, Schweer H, Seyberth HW. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002;17:332-6.

Hofmeyr GJ, Walraven G, Gülmezoglu AM, Maholwana B, Alfirevic Z, Villar J. Misoprostol to treat postpartum haemorrhage: a systematic review. BJOG. 2005;112:547-53.

Lokugamage AU, Sullivan KR, Niculescu I, Tigere P, Onyangunga F, Refaey HE, et al. A randomized study comparing rectally administered misoprostol versus syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstet Gynecol Scand. 2001;80:835-9.

Othman ER, Fayez MR, Abd El Aal DEM, Mohamed HSE, Abbas AM, Ali MK. Sublingual misoprostol versus intravenous oxytocin in reducing bleeding during and after cesarean section: a randomized clinical trial. Taiwan J Obstet Gynecol. 2016;55:791-5.

Fekih M, Jnifene A, Fathallah K, Ben Regaya L, Memmi A, Bouguizene S et al. Benefit of misoprostol for prevention of postpartum hemorrhage in cesarean section: a randomized controlled trial. J Gynecol Obstet Biol Reprod (Paris). 2009;38(7):588-93.

Lapaire O, Schneider MC, Stotz M, Surbek DV, Holzgreve W, Hoesli IM. Oral misoprostol vs intravenous oxytocin in reducing blood loss after emergency cesarean delivery. Int J Gynecol Obstet. 2006;95(1):2-7.

Singh G, Radhakrishnan G, Guleria K. Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. Int J Gynaecol Obstet. 2009;107(2):130-4.

Chaudhuri P, Biswas J, Mandal A. Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in low-risk women. Int J Gynaecol Obstet. 2012;116(2):138-142.

Larsson C, Saltvedt S, Wiklund I, Pahlen S, Andolf E. Estimation of blood loss after caesarean section and vaginal delivery has low validity with a tendency to exaggeration. Acta Obstet Gynecol Scand. 2006;85:1448-52.

Lee MH, Ingvertsen BT, Kirpensteijn J, Jensen AL, Kristensen AT. Quantification of surgical blood loss. Vet Surg. 2006;35(4):388-93.